Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

Elif Aras, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)
Kamer Tecen Yücel, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)
Aygın Bayraktar Ekincioğlu, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)
İbrahim Güllü (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)
Clinical and Experimental Health Sciences
9 2
Yıl: 2019 Cilt: 9 Sayı: 2 Sayfa Aralığı: 178 - 191 Metin Dili: İngilizce DOI: 10.33808/clinexphealthsci.469538 İndeks Tarihi: 12-11-2020

Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

Öz:
Objective: Capecitabine, a prodrug of 5-fluorouracil, is currently used in the treatment of metastatic colorectal and breast cancers. The aim of thisstudy was to review the pharmacological mechanisms, treatment strategies, and documented case reports of capecitabine-induced hand–footsyndrome (HFS).Methods: All case reports documented in the PubMed, Web of Science, and Scopus databases up to February 2018 were searched and reviewedusing the keywords capecitabine, hand-foot syndrome, and case report.Results: The database search identified 373 articles in the literature; of these, 88 articles (having 111 case reports) in the English or Turkish languagehaving a full-text access were included in the study. The median duration of capecitabine-induced HFS was 28 (range, 7–140) days, and the dailydose of capecitabine ranged between 850 and 5000 mg/m2 in cases wherein capecitabine was applied as monotherapy(n=19). A dose reductionor treatment discontinuation, systemic or topical treatment alone or in combination, and the use of henna, vitamin E, or pyridoxine were preferredoptions in the treatment of HFS.Conclusion: Health care providers and patients should be aware of developing capecitabine-induced HFS and its risk factors. Early recognition andtreatment initiation for HFS are important to maintain effective chemotherapy in patients with cancer.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Laboratories, R, Xeloda† product information. Retrieved from http://www.rocheusa.com/ products/ xeloda/pi.pdf, April 2006.
  • [2] Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16(8): 1289-96.
  • [3] Pendharkar D, Goyal H. Novel & effective management of capecitabine induced Hand Foot Syndrome. J Clin Oncol 2004. 22(14_suppl): 8105.
  • [4] Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71(4): 787-94.
  • [5] Gressett SM, Stanford BL, Hardwicke F. Management of handfoot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12(3): 131-41.
  • [6] Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004; 18(9): 1161-8, 1173; discussion 1173-6, 1181-4.
  • [7] Webster-Gandy JD, How C,Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007; 11(3): 238-46.
  • [8] Queckenberg C, Erlinghagen V, Baken BC, Van Os SH, Wargenau M, Kubeš V, et al. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations. Cancer Chemother Pharmacol 2015; 76(5): 1081-91.
  • [9] Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1(4): 225-34.
  • [10] Cohen PR. Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine. Cureus 2017; 9(1): 969.
  • [11] Mikoshiba N, Yamamoto-Mitani N, Ohki T, Asaoka Y, Yamaguchi H, Obi S, et al. A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients. Jpn J Clin Oncol 2016.
  • [12] Murugan K, Ostwal V, Carvalho MD, D’souza A, Achrekar MS, Govindarajan S, et al. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. Support Care Cancer 2016; 24(6): 2575-81.
  • [13] Anderson RT, Keating KN, Doll HA, Camacho F. The HandFoot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist 2015; 20(7): 831-8.
  • [14] Takeda K, Shigemasu T, Shirai M, Yamanda T. Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy]. Gan To Kagaku Ryoho 2012; 39 Suppl 1: 74-6.
  • [15] Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008; 66(1): 88-95.
  • [16] Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabineinduced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16(12 Suppl No 14): 31-7.
  • [17] Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res 2015; 125: 217-43.
  • [18] Gerbrecht BM.Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 2003; 26(2): 161-7.
  • [19] Hindenburg AA, Matthews L. Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report. Int J Gynecol Cancer 2003; 13(6): 898-900.
  • [20] Schull BW, Scheithauer W, Kornek GV. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 2003; 26(6): 578-80.
  • [21] Jones KL, Valero V. Capecitabine-induced pancreatitis. Pharmacotherapy, 2003; 23(8): 1076-8.
  • [22] LoRusso PM. Capecitabine and PPE syndrome: a case report. Breast J 2003; 9(1): 64-5.
  • [23] Clippe C, Freyer G, Milano G, Trillet-Lenoir V. Lethal toxicity of capecitabine due to abusive folic acid prescription? Clin Oncol (R Coll Radiol) 2003; 15(5): 299-300.
  • [24] Allen J, Williamson S. Over compliance with capecitabine oral chemotherapy. Int J Clin Pharm 2014; 36(2): 271-3.
  • [25] Niemann B, Rochlitz C, Herrmann R, Pless M. Toxic encephalopathy induced by capecitabine. Oncology 2004; 66(4): 331-5.
  • [26] Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 2006; 16(8): 801-10.
  • [27] Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006; 6(3): 219-23.
  • [28] Inui T, Asakawa A, Morita Y, Mizuno S, Natori T, Kawaguchi A, et al. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 2006; 260(5): 484-7.
  • [29] Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006; 5(5): 359-62.
  • [30] Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN. Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report. J Clin Neuromuscul Dis 2006; 7(3): 128-32.
  • [31] Vogt T, Coras B, Hafner C, Landhaler M, Reichlw A. Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes. Lancet Oncol 2006; 7(8): 695-7.
  • [32] Saini KS, Attili SV, Saini ML, Batra U, Lakshmaiah KC, Acharya R, et al. Capecitabine induced Hand foot Syndrome. HİACM 2007; 8(2): 144-5.
  • [33] Tavares-Bello R. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient. J Eur Acad Dermatol Venereol 2007; 21(10): 1434-5.
  • [34] Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 2007; 6(5): 382-5.
  • [35] Lee SD, Kim HJ, Hwang SJ, Kim YJ, Nam SH, Kim BS. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med 2007; 22(2): 109-12.
  • [36] Bosch TM, Meijerman I, Beijnen JH, van Thiel SW, Vlasveld T. Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma. Ann Oncol 2007; 18(3): 607-8.
  • [37] Bianconi M, Jankilevich G, Otero S, Nassif J, Storino C. Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol 2007; 106(1): 268-71.
  • [38] Cho HJ, Kim SJ, Kim SY, Han HS, Hong YS, Kim SH, et al. Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer. Cancer Chemother Pharmacol 2009; 63(3): 549-53.
  • [39] Yucel I, Guzin G. Topical henna for capecitabine induced handfoot syndrome. Invest New Drugs 2008; 26(2): 189-92.
  • [40] Trindade F, Haro R, Fariña MC, Requena L. Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine. Am J Dermatopathol 2008; 30(2): 172-3.
  • [41] Vickers MM, Easaw JC. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. J Gastrointest Cancer 2008; 39(1-4): 141-3.
  • [42] Surjushe A, Vasani R, Medhekar S, Thakre M, Saple DG. Handfoot syndrome due to capecitabine. Indian J Dermatol 2008; 53(1): 43-4.
  • [43] Goutos I, Kaniorou-Larai M, Dziewulski P. “Hand-foot” syndrome-an unusual case of plantar pathology presenting to a burns unit. J Burn Care Res 2009; 30(3): 529-32.
  • [44] Endrizzi BT, Lee PK. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg 2009; 35(10): 1567-72.
  • [45] VillalonG, Martín JM, Pinazo MI, Calduch L, Alonso V, Jordá E. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. Am J Clin Dermatol 2009; 10(4): 261-3.
  • [46] Lo´ pez V, Martı´n JM, E Jorda E. Severe palmar–plantar erytrodysesthesia after treatment with capecitabine. J Eur Acad Dermatol Venereol 2010; 24(1): 106.
  • [47] Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol, 2009. 20(7): 1281.
  • [48] Baena-Canada JM, Martínez MJ, García-Olmedo O, JiménezBárcenas R, Muriel-Cueto P. Interaction between capecitabine and brivudin in a patient with breast cancer. Nat Rev Clin Oncol 2010; 7(1): 55-8.
  • [49] Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O, et al. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010; 29(2): 140-2.
  • [50] Gafson AR, Goodkin O, Begent R. Observations and hypothesis on an individual patient topically treated for capecitabineinduced Palmar-Plantar syndrome. BMJ Case Rep 2010; 2010.
  • [51] Vasudevan B. An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of handfoot syndrome or a separate entity? Indian J Pharmacol 2010; 42(5): 326-8.
  • [52] Bayraktar S, Garcia-Buitrago MT, Hurley E, Gluck S. Surviving metastatic breast cancer for 18 years: a case report and review of the literature. Breast J 2011; 17(5): 521-4.
  • [53] Gordon VL, Harding GA, Czaykowski P. Capecitabine-induced, nonneutropenic enterocolitis. J Gastrointest Cancer 2011; 42(4): 278-81.
  • [54] Serdar ZA, Gönenç I, Yaşar Ş, Doruk T, Döner N. Hand-Foot Syndrome Accompanied by Severe Oral Lesions during Capecitabine Therapy for Metastatic Colon Carcinoma. Marmara Medical Journal 2011; 24: 200-2.
  • [55] Qiao J, Fang H. Hand-foot syndrome related to chemotherapy. CMAJ, 2012. 184(15): 818.
  • [56] Almeida da Cruz L, Hoff PM, Ferrari CL, Riechelmann RS. Unilateral hand-foot syndrome: does it take sides? Case report and literature review. Clin Colorectal Cancer 2012; 11(1): 82-4.
  • [57] Sanghi S, Grewal RS, Brig, Vasudevan B, Nagure A. Capecitabine induced Hand-Foot Syndrome: Report of two cases. Med J Armed Forces India 2013; 69(1): 65-7.
  • [58] Chan HY, Ng CM, Tiu SC, Chan AO, Shek CC. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine? Hong Kong Med J 2012; 18(6): 526-9.
  • [59] Lipshitz J, Astrow AB, Xu Y. A unique and as yet unexplored subset of metastatic colorectal cancer: widespread lymphnode-only recurrence. J Gastrointest Cancer 2013; 44(4): 466- 71.
  • [60] Tanaka Y, Oura S, Yoshimasu T, Ohta F, Naito K, Nakamura R, et al. Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case report. Case Rep Oncol 2013; 6(1): 1-5.
  • [61] Marinelli S, Granito A,Piscaglia F, Renzulli M, Stagni A, Bolondi L. Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon 2013; 13(9): 11721.
  • [62] Inokuchi M, Ishikawa S, Furukawa H, Takamura H, Ninomiya I, Kitagawa H, et al., Treatment of capecitabine-induced handfoot syndrome using a topical retinoid: A case report. Oncol Lett 2014; 7(2): 444-448.
  • [63] Perri F, Muto P, Argenone A, Ionna F, Longo F, Fulciniti F, et al. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study. Oncology 2013; 84(4): 251-4.
  • [64] Mishra A, Shrestha PR, Ramanna Rao RV, Kumar A. Nasal involvement in hand and foot syndrome. Indian J Dermatol 2013; 58(2): 164.
  • [65] Ilyas S, Wasif K, Saif MW. Topical henna ameliorated capecitabine-induced hand-foot syndrome. Cutan Ocul Toxicol 2014; 33(3): 253-5.
  • [66] Prakasam PJ, Krishnan DG, Mohanta GP. A Case Report on Capecitabine Induced Hand Foot Syndrome and Mucositis. Indian Journal of Pharmacy Practice 2014; 7(4): 47-49.
  • [67] Parikh SA, Markovic SN, Brewer JD. Oral capecitabine to prevent recurrent cutaneous squamous cell carcinoma in a lung transplant recipient. Int J Dermatol 2015; 54(9): 358-60
  • [68] Elmas OF, Metin MS, Kızılyel O, Aktaş A, Birdal C. [A case of palmoplantar dysesthesia syndrome caused by capecitabine]. Agri 2016; 28(1): 54-6.
  • [69] Li Z, Jiang N, Xu Y. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy. Australas J Dermatol 2016; 57(1): 14-6.
  • [70] Rovere RK, De Lima AS. Forbidden to Drive - a New Chemotherapy Side Effect. Klin Onkol 2015; 28(5): 370-2.
  • [71] Mazza C, Slimano F, Visseaux L, Ordab MA, Botsen D, Grange F, et al. Capecitabine and adermatoglyphia: trouble in border! J Eur Acad Dermatol Venereol 2017; 31(6): 283-284.
  • [72] Chen GY, Chang TW, Chen WC. Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases. Br J Dermatol 2003; 148(5): 1071-3.
  • [73] Uslu G, Karaman G, Uslu M, Şavk E, Şendur N, Meydan N. Kapesitabin Tedavisi Alan Hastada Gelişen El-Ayak Sendromu. ürkderm 2006; 40: 105-7.
  • [74] Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006; 15(3): 414-24.
  • [75] Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 2006; 7(2): 164-6.
  • [76] Goyal R, Chalamalasetty SB, Madan K, Paul SB, Arora R, Safaya R, et al. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma. Indian J Gastroenterol 2007; 26(6): 292-3.
  • [77] Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 2009; 16(1): 88-92.
  • [78] Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol 2008; 27(4): 311-5.
  • [79] Karatay E, Akbal E, Koca D, Gönülalan G, Altinbaş M. Kapesitabin tedavisi alan hastada gelişen atipik el ayak sendromu: Olgu sunumu. Türk Onkoloji Dergisi 2008; 23(3): 140-141.
  • [80] Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer 2009; 8(4): 231-4.
  • [81] Mignogna MD, Fortuna G, Falleti J, Leuci S. Capecitabineinduced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. Eur J Clin Pharmacol 2009; 65(10): 1057- 9.
  • [82] Baretta Z, Ghiotto C, Marino D, Jirillo A. Aloe-induced hypokalemia in a patient with breast cancer during chemotherapy. Ann Oncol 2009; 20(8): 1445-6.
  • [83] Vrdoljak E, Mise BP, Lukić B, Curić Z, Bosković L, Tica I. Longlasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine-- case report. Onkologie; 2010; 33(1-2): 53-6.
  • [84] Yoshida Y, Hoshino S, Shiwaku H, Beppu R, Tanimura S, Tanaka S, et al. Early start of chemotherapy after resection of primary colon cancer with synchronous multiple liver metastases: a case report. Case Rep Oncol 2011; 4(2): 250-4.
  • [85] Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA. Capecitabineinduced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol 2011; 147(12): 1418-23.
  • [86] Akash SS, Bhounsule AS. Oral Capecitabine - Can It Cause The Hand-Foot Syndrome? Journal of Clinical and Diagnostic Research 2011; 5(2): 376-378.
  • [87] Ferreira A, Vieira C, Rodrigues A, Pereira D, Rodrigues H, Dávila C, et al. Bevacizumab in the treatment of metastatic breast cancer: three case reports. Curr Opin Oncol 2011; 23 Suppl: 11-9.
  • [88] Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011; 29(8): 203-5.
  • [89] Ozkan C, Arslan C, Kılıc MK, Erman M, Altundag K, Pituitary Gland Metastasis of Breast Cancer: A Case Report. International Journal of Hematology and Oncology, 2011. 21
  • [90] Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist 2012; 17(2): 291-3.
  • [91] Rolski J,Karczmarek-Borowska, Smietana A. The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) 2012; 16(6): 582-5.
  • [92] Yan S, Jiang X, Yang J, Yan D, Wang YX. Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. Cancer Biother Radiopharm 2012; 27(8): 519-23.
  • [93] Uleer C, Yazdan-Pourfard J, Holland B, Karl-Friedrich B, MoisidisTesch C, von Minckwitz G. Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care (Basel) 2012; 7(1): 45-47.
  • [94] Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, et al. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer 2013; 16(1): 122-6.
  • [95] Lal HS. Hand and foot syndrome secondary to capecitabine. Indian J Dermatol Venereol Leprol 2014; 80(5): 427-30.
  • [96] Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Sasaki T, et al. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. Case Rep Oncol 2014; 7(1): 117-21.
  • [97] Kigen G, Busakhala N, Njiru E, Chite F, Loehrer P. Palmarplantar erythrodysesthesia associated with capecitabine chemotherapy: a case report. Pan Afr Med J 2015; 21: 228.
  • [98] Matsuda S, Koketsu H, Hayakawa M, Nagata N. Unilateral Capecitabine-related Hand-foot Syndrome. Intern Med 2015; 54(21): 2779.
  • [99] Chavarri-Guerra Y, Sote-Perez-de-Celis E. Loss of Fingerprints. N Engl J Med, 2015. 372(16). [100]Del Re M, Quaquarini E, Sottotetti F, Michelucci A, Palumbo R, Simi P, et al. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. Pharmacogenomics 2016; 17(1): 5-9.
  • [101]Takeshita N, Fukunaga T, Kimura M, Sugamoto Y, Tasaki K, Hoshino I,et al.Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer. World J Gastroenterol 2015; 21(44): 12722-8.
  • [102]Lightowlers S, Soomal R. Loss of fingerprints secondary to palmoplantar erythrodysesthesia in a patient on capecitabine chemotherapy. BMJ 2015; (35): 6023.
  • [103]Hashida H, Satake H, Kaihara S. A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy. Case Rep Oncol 2017; 10(1): 81-85.
  • [104]Ljubojevic Hadzavdic S, Stulhofer Buzina D, Murtezani I, Skerlev M. Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. J Eur Acad Dermatol Venereol 2017; 31(6): 304-306.
  • [105]Singh B, Tripathy T, Kar BR, Singh S. Involvement of scars in capecitabine induced hand foot syndrome. Indian J Dermatol Venereol Leprol 2018; 84(1): 85-87.
  • [106]Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, et al. Hand-foot syndrome in patients treated with capecitabinecontaining combination chemotherapy. J Clin Pharmacol 2004; 44(10): 1166-72.
  • [107]Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77(5): 257-71.
  • [108]Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, et al. Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy. Ann Pharmacother 2015; 49(10): 1120- 4.
  • [109]Naito M, Yamamoto T, Hara S, Shimamoto C, Miwa Y. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen. Chemotherapy 2017; 62(1): 23-29.
  • [110]Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol 2016; 41(1): 8-15.
  • [111]Marse H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8 (Suppl 1): 16-30.
  • [112]Limited, H.-L.R., XELODA® product monograph. Mississauga, Ontario, 31 July 2002.
  • [113]Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 2014; 22(6): 1585-93.
  • [114]Zhou Y, Peng L, Li Y, Chen L. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced handfoot syndrome: A meta-analysis. Biomed Rep 2013; 1(6): 873- 878.
  • [115]Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC, Hutchins KS. Pyridoxine treatment and prevention of handand-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 2003; 9: 161-66.
  • [116]Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol 2015; 40(3): 260-70.
  • [117]Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8( Suppl 1): 31-40.
  • [118]Brown J, Burck K, Black D, Collins C. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991; 24(6 Pt 1): 1023-5.
  • [119]Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011; 16(11): 1508-19.
  • [120]Serrano Fernandez MP, Gutiérrez Vilella MJ, Pérez MartínPalanco A, Vanaclocha Sebastián F, Cabezón Gutiérrez L. [Palmar-plantar erythrodysaesthesia syndrome local cold prevention]. Rev Enferm 2011; 34(9): 42-6.
APA ARAS-ATIK E, Tecen Yücel K, Bayraktar-Ekincioglu A, GÜLLÜ İ (2019). Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. , 178 - 191. 10.33808/clinexphealthsci.469538
Chicago ARAS-ATIK Elif,Tecen Yücel Kamer,Bayraktar-Ekincioglu Aygin,GÜLLÜ İbrahim Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. (2019): 178 - 191. 10.33808/clinexphealthsci.469538
MLA ARAS-ATIK Elif,Tecen Yücel Kamer,Bayraktar-Ekincioglu Aygin,GÜLLÜ İbrahim Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. , 2019, ss.178 - 191. 10.33808/clinexphealthsci.469538
AMA ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. . 2019; 178 - 191. 10.33808/clinexphealthsci.469538
Vancouver ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. . 2019; 178 - 191. 10.33808/clinexphealthsci.469538
IEEE ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ "Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports." , ss.178 - 191, 2019. 10.33808/clinexphealthsci.469538
ISNAD ARAS-ATIK, Elif vd. "Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports". (2019), 178-191. https://doi.org/10.33808/clinexphealthsci.469538
APA ARAS-ATIK E, Tecen Yücel K, Bayraktar-Ekincioglu A, GÜLLÜ İ (2019). Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. Clinical and Experimental Health Sciences, 9(2), 178 - 191. 10.33808/clinexphealthsci.469538
Chicago ARAS-ATIK Elif,Tecen Yücel Kamer,Bayraktar-Ekincioglu Aygin,GÜLLÜ İbrahim Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. Clinical and Experimental Health Sciences 9, no.2 (2019): 178 - 191. 10.33808/clinexphealthsci.469538
MLA ARAS-ATIK Elif,Tecen Yücel Kamer,Bayraktar-Ekincioglu Aygin,GÜLLÜ İbrahim Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. Clinical and Experimental Health Sciences, vol.9, no.2, 2019, ss.178 - 191. 10.33808/clinexphealthsci.469538
AMA ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. Clinical and Experimental Health Sciences. 2019; 9(2): 178 - 191. 10.33808/clinexphealthsci.469538
Vancouver ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports. Clinical and Experimental Health Sciences. 2019; 9(2): 178 - 191. 10.33808/clinexphealthsci.469538
IEEE ARAS-ATIK E,Tecen Yücel K,Bayraktar-Ekincioglu A,GÜLLÜ İ "Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports." Clinical and Experimental Health Sciences, 9, ss.178 - 191, 2019. 10.33808/clinexphealthsci.469538
ISNAD ARAS-ATIK, Elif vd. "Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports". Clinical and Experimental Health Sciences 9/2 (2019), 178-191. https://doi.org/10.33808/clinexphealthsci.469538
Sayfa Oluşturulma Tarihi
30-04-2024 8:8

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları